参考文献:1. Meunier I, Pillet S, Simonsen JN, Von Messling V (2010) Influenza pathogenesis: lessons earned from animal studies with H5N1, H1N1 Spanish, and pandemic H1N1 2009 influenza. Crit Care Med 38:e21–e29. doi:10.1097/CCM.0b013e3181c8b4d5 CrossRef 2. Shinde V, Bridges CB, Uyeki TM et al (2009) Triple-reassortant swine influenza A (H1), in humans in the United States, 2005-009. N Engl J Med 360:2616-625. doi:10.1056/NEJMoa0903812 CrossRef 3. Perez-Padilla R, De la Rosa-Zamboni D, Ponce de León S et al (2009) Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 361:680-89. doi:10.1056/NEJMoa0904252 CrossRef 4. Bermejo-Martin JF, Martin-Loeches I, Rello J et al (2010) Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 14:R167. doi:10.1186/cc9259 CrossRef 5. Lee N, Wong CK, Chan PK et al (2011) Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 6:e26050. doi:10.1371/journal.pone.0026050 CrossRef 6. Bautista E, Arcos M, Jimenez-Alvarez L et al (2013) Angiogenic and inflammatory markers in acute respiratory distress syndrome and renal injury associated to A/H1N1 virus infection. Exp Mol Pathol 94:486-92. doi:10.1016/j.yexmp.2013.03.007 CrossRef 7. Crouch E (2000) Surfactant protein D and pulmonary host defense. Respir Res 1:93-08. doi:10.1186/rr19 CrossRef 8. Hartshorn K, White M, Tecle T, Sorensen G, Holmskov U, Crouch E (2010) Viral aggregating and opsonizing activity in collectin trimers. Am J Physiol Lung Cell Mol Physiol 298:L79–L88. doi:10.1186/rr19 CrossRef 9. Gallo R, Nizet V (2008) Innate barriers against infection and associated disorders. Drug Discov Today 5:145-52. doi:10.1016/j.ddmec.2008.04.009 CrossRef 10. Pastva A, Wright J, Williams K (2007) Immunomodulatory roles of surfactant proteins A and D. Implications in lung disease. Proc Am Thor Soc 4:252-57. doi:10.1513/pats.200701-018AW CrossRef 11. Greene K, Wright J, Steinberg K (1999) Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 160:1843-850. doi:10.1164/ajrccm.160.6.9901117 CrossRef 12. Winkler C, Atochina-Vasserman E, Holz O et al (2011) Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir Res 12:29. doi:10.1186/1465-9921-12-29 CrossRef 13. Bernard GR, Artigas A, Brigham KL et al (1994) The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trials coordination. Am J Respir Crit Care Med 149:818-24. doi:10.1164/ajrccm.149.3.7509706 CrossRef 14. Honda Y, Kuroki Y, Matsuura E et al (1995) Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 152:1860-866. doi:10.1164/ajrccm.152.6.
刊物类别:Medicine
刊物主题:Medicine & Public Health Pneumology and Respiratory System
出版者:Springer New York
ISSN:1432-1750
文摘
Introduction Surfactant protein D (SP-D) plays an important role in the innate responses against pathogens and its production is altered in lung disorders. Methods We studied the circulating levels of SP-D in 37 patients with acute respiratory distress syndrome due to the A/H1N1 virus infection and in 40 healthy controls. Cox logistic regression models were constructed to explore the association of SP-D levels and risk of death. Results Mortality rate after a 28-day was 32.42?%. Significant higher levels of SP-D were detected in A/H1N1 patients with fatal outcome (p?p?=?0.043). Conclusions Our results revealed that higher circulating levels of SP-D are associated with higher mortality risk in critically ill A/H1N1 patients. SP-D might be a predictive factor of poor outcomes in viral pneumonia.